secwatch.observer — SEC 8-K summary
======================================

Issuer:     KALA BIO, Inc. (KALA)
CIK:        0001479419
Form:       8-K
Filed at:   2026-09-10T21:24:54+00:00
Accession:  0001829126-26-009999
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kala Bio secures exclusive US distribution rights for Virotek ophthalmology genetic testing program
--------------------------------------------------------------------------------

- Exclusive 5-year distribution deal with Virotek for ophthalmology genetic testing/screening program in US, effective Sept 3, 2026.
- Profit split 50/50 after Virotek recovers COGS; Kala handles commercial development, Virotek delivery/administration.
- Exclusivity conditioned on Kala meeting milestone by Sept 3, 2027; failure converts to non-exclusive after 30-day cure.
- Kala gets right of first refusal on any sale/license of Virotek's ophthalmology products; term renewable by mutual agreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1479419/000182912626009999/0001829126-26-009999-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1479419/000182912626009999/kalabio_8k.htm
  HTML page:      https://secwatch.observer/filing/0001829126-26-009999

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer